<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer Res</journal-id><journal-title-group><journal-title>Breast Cancer Research : BCR</journal-title></journal-title-group><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4531540</article-id><article-id pub-id-type="pmid">26243145</article-id><article-id pub-id-type="publisher-id">621</article-id><article-id pub-id-type="doi">10.1186/s13058-015-0621-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Human breast cancer cells educate macrophages toward the M2 activation status </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4368-4866</contrib-id><name><surname>Sousa</surname><given-names>Sofia</given-names></name><address><phone>+358(0)503164101</phone><email>sofia.sousa@uef.fi</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Brion</surname><given-names>Régis</given-names></name><address><email>regis.brion@univ-nantes.fr</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Lintunen</surname><given-names>Minnamaija</given-names></name><address><email>minnamaija.lintunen@utu.fi</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Kronqvist</surname><given-names>Pauliina</given-names></name><address><email>paukro@utu.fi</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Sandholm</surname><given-names>Jouko</given-names></name><address><email>jouko.sandholm@btk.fi</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Mönkkönen</surname><given-names>Jukka</given-names></name><address><email>jukka.monkkonen@uef.fi</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kellokumpu-Lehtinen</surname><given-names>Pirkko-Liisa</given-names></name><address><email>pirkko-liisa.kellokumpu-lehtinen@uta.fi</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Lauttia</surname><given-names>Susanna</given-names></name><address><email>susanna.lauttia@helsinki.fi</email></address><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Tynninen</surname><given-names>Olli</given-names></name><address><email>olli.tynninen@hus.fi</email></address><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Joensuu</surname><given-names>Heikki</given-names></name><address><email>heikki.joensuu@hus.fi</email></address><xref ref-type="aff" rid="Aff8"/><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Heymann</surname><given-names>Dominique</given-names></name><address><email>dominique.heymann@univ-nantes.fr</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Määttä</surname><given-names>Jorma A.</given-names></name><address><email>jorma.maatta@utu.fi</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff5"/></contrib><aff id="Aff1"><label/>School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Yliopistonranta 1C, P.O. Box 1627, FI-70211 Kuopio, Finland </aff><aff id="Aff2"><label/>INSERM, UMR957, Equipe LIGUE 2012, Nantes, F-44035 France </aff><aff id="Aff3"><label/>Université de Nantes, Nantes atlantique universités, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, F-44035 France </aff><aff id="Aff4"><label/>CHU de Nantes, Nantes, F-44035 France </aff><aff id="Aff5"><label/>Institute of Biomedicine, Department of Cell Biology and Anatomy, University of Turku, Turku, Finland </aff><aff id="Aff6"><label/>Cell Imaging Core, Turku Centre for Biotechnology, University of Turku, and Åbo Akademi University, Turku, Finland </aff><aff id="Aff7"><label/>Medical School, University of Tampere and Department of Oncology Tampere University Hospital, Tampere, Finland </aff><aff id="Aff8"><label/>Laboratory of Molecular Oncology, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland </aff><aff id="Aff9"><label/>Department of Pathology, Haartman Institute, University of Helsinki and HUSLAB, Helsinki, Finland </aff><aff id="Aff10"><label/>Comprehensive Cancer Center, Helsinki University Hospital, and Department of Oncology, University of Helsinki, Helsinki, Finland </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>17</volume><issue>1</issue><elocation-id>101</elocation-id><history><date date-type="received"><day>24</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>21</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>© Sousa et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><text><SENT sid="1" pm="."><plain>Introduction </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>The immune system plays a major role in cancer progression. </plain></SENT>
<SENT sid="3" pm="."><plain>In solid tumors, 5-40 % of the tumor mass consists of tumor-associated macrophages (TAMs) and there is usually a correlation between the number of TAMs and poor prognosis, depending on the tumor type. </plain></SENT>
<SENT sid="4" pm="."><plain>TAMs usually resemble M2 macrophages. </plain></SENT>
<SENT sid="5" pm="."><plain>Unlike M1-macrophages which have pro-inflammatory and anti-cancer functions, M2-macrophages are immunosuppressive, contribute to the matrix-remodeling, and hence favor tumor growth. </plain></SENT>
<SENT sid="6" pm="."><plain>The role of TAMs is not fully understood in breast cancer progression. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="7" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="8" pm="."><plain>Macrophage infiltration (CD68) and activation status (HLA-DRIIα, CD163) were evaluated in a large cohort of human primary breast tumors (562 tissue microarray samples), by immunohistochemistry and scored by automated image analysis algorithms. </plain></SENT>
<SENT sid="9" pm="."><plain>Survival between groups was compared using the Kaplan-Meier life-table method and a Cox multivariate proportional hazards model. </plain></SENT>
<SENT sid="10" pm="."><plain>Macrophage education by breast cancer cells was assessed by ex vivo differentiation of peripheral blood mononuclear cells (PBMCs) in the presence or absence of breast cancer cell conditioned media (MDA-MB231, MCF-7 or T47D cell lines) and M1 or M2 inducing cytokines (respectively IFN-γ, IL-4 and IL-10). </plain></SENT>
<SENT sid="11" pm="."><plain>Obtained macrophages were analyzed by flow cytometry (CD14, CD16, CD64, CD86, CD200R and CD163), ELISA (IL-6, IL-8, IL-10, monocyte colony stimulating factor M-CSF) and zymography (matrix metalloproteinase 9, MMP-9). </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="12" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="13" pm="."><plain>Clinically, we found that high numbers of CD163+ M2-macrophages were strongly associated with fast proliferation, poor differentiation, estrogen receptor negativity and histological ductal type (p&lt;0.001) in the studied cohort of human primary breast tumors. </plain></SENT>
<SENT sid="14" pm="."><plain>We demonstrated ex vivo that breast cancer cell-secreted factors modulate macrophage differentiation toward the M2 phenotype. </plain></SENT>
<SENT sid="15" pm="."><plain>Furthermore, the more aggressive mesenchymal-like cell line MDA-MB231, which secretes high levels of M-CSF, skews macrophages toward the more immunosuppressive M2c subtype. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="16" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="17" pm="."><plain>This study demonstrates that human breast cancer cells influence macrophage differentiation and that TAM differentiation status correlates with recurrence free survival, thus further emphasizing that TAMs can similarly affect therapy efficacy and patient outcome. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="18" pm="."><plain>Electronic supplementary material </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="19" pm="."><plain>The online version of this article (doi:10.1186/s13058-015-0621-0) contains supplementary material, which is available to authorized users. </plain></SENT>
</text></SecTag></p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec id="Sec1" sec-type="introduction"><title><text><SENT sid="20" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="21" pm="."><plain>Metastasis is often explained with the ‘seed and soil’ theory. </plain></SENT>
<SENT sid="22" pm="."><plain>Conceptually, it implies that the cancer cell (seed) undergoes epithelial to mesenchymal transition (EMT), invades vessels, becomes a circulating tumor cell (CTC), migrates, extravasates, undergoes mesenchymal to epithelial transition, and eventually colonizes distant sites as a disseminating tumor cell (DTC). ‘Soil’ relates to tumor microenvironment elements which contribute to these processes, making the distant sites permissive to colonization by CTCs or DTCs [1]. </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>The immune system is a major player in the cancer cell/tumor microenvironment crosstalk. </plain></SENT>
<SENT sid="24" pm="."><plain>In solid tumors, 5−40 % of the tumor mass consists of tumor-associated macrophages (TAMs). </plain></SENT>
<SENT sid="25" pm="."><plain>Approximately 80 % of the publications in this field report an association between TAMs and poor prognosis [2, 3]. </plain></SENT>
<SENT sid="26" pm="."><plain>In humans macrophage polarization is a continuum that spans two extremes from the classically activated M1 macrophages to the alternatively activated M2 macrophages. </plain></SENT>
<SENT sid="27" pm="."><plain>M1 macrophages derive from interferon γ (IFN-γ) or lipopolysaccharide (LPS) stimuli and secrete inflammatory cytokines (e.g., IL-6, IL-12, reactive oxygen species (ROS), reactive nitrogen species (RN) and TNF-α). </plain></SENT>
<SENT sid="28" pm="."><plain>The validated surface-markers of human M1 macrophages include high levels of CD14 and CD16, CD64, CD86 and HLA-DRα [4, 5]. </plain></SENT>
<SENT sid="29" pm="."><plain>M2 macrophages, can be further divided into M2a, M2b and M2c macrophages. </plain></SENT>
<SENT sid="30" pm="."><plain>M2a macrophages arise from IL-4 or IL-13 stimuli and release matrix-remodeling cytokines. </plain></SENT>
<SENT sid="31" pm="."><plain>Elevated expression of CD200R and CD86 is a validated phenotypic marker of M2a macrophages [4, 5]. </plain></SENT>
<SENT sid="32" pm="."><plain>M2b macrophages result from the recognition of immune complexes in combination with IL-1β or LPS stimuli and like M2a macrophages, they are involved in wound healing. </plain></SENT>
<SENT sid="33" pm="."><plain>The immunosuppressive M2c-macrophages are the outcome of IL-10, TGF-β (transforming growth factor β), glucocorticoids or immune complex rich environments. </plain></SENT>
<SENT sid="34" pm="."><plain>M2c macrophages generate further IL-10 and matrix-remodeling factors such as matrix metalloproteinases (MMPs) [4, 5]. </plain></SENT>
<SENT sid="35" pm="."><plain>Elevated CD163 expression is a validated marker of M2c polarization [5]. </plain></SENT>
</text></p><p><text><SENT sid="36" pm="."><plain>TAMs, a macrophage population recruited and educated by tumor cells, which are therefore exposed to IL-10, TGF-β, M-CSF (monocyte colony stimulating factor) [6] and other immunosuppressive stimuli [7], are more closely related to the M2 type [8]. </plain></SENT>
<SENT sid="37" pm="."><plain>In the tumor microenvironment, TAMs will preferentially perform trophic and immunosuppressive rather than immune effector tasks [3, 9, 10]. </plain></SENT>
<SENT sid="38" pm="."><plain>Hence, TAMs promote epithelial outgrowth and invasion, which are common features of development and cancer [3, 9]. </plain></SENT>
<SENT sid="39" pm="."><plain>Wickoff et al. have shown that mammary tumors exhibit a paracrine loop between TAMs and cancer cells. </plain></SENT>
<SENT sid="40" pm="."><plain>TAMs express monocyte colony stimulating factor receptor (M-CSFR, also known as CSF-1R or cFMS), which binds monocyte colony stimulating factor (M-CSF, also known as CSF-1) secreted by cancer cells. </plain></SENT>
<SENT sid="41" pm="."><plain>Conversely, TAMs secrete epidermal growth factor (EGF) and activate the EGF receptor (EGFR) on the cancer cells. </plain></SENT>
<SENT sid="42" pm="."><plain>This allows co-migration of the two cell types, thus, enhancing motility and subsequent invasion of healthy surrounding tissue and intravasation [11, 12]. </plain></SENT>
<SENT sid="43" pm="."><plain>Also, breast cancer cell leucocyte receptor, vascular cell adhesion molecule 1 (VCAM1) binding to TAM α4-integrin explains the increased survival of VCAM1+ tumor cells in leucocyte-rich environments [13]. </plain></SENT>
</text></p><p><text><SENT sid="44" pm="."><plain>Like their phenotype and interactions with tumor cells, the location of TAMs in relation to hypoxic areas is a key parameter controlling tumor growth. </plain></SENT>
<SENT sid="45" pm="."><plain>In addition to the perivascular TAMs, which take part in cancer cell invasion [11, 12], TAMs are also recruited into hypoxic areas [14]. </plain></SENT>
<SENT sid="46" pm="."><plain>Within these avascular areas TAMs alter their gene expression profile, favoring a pro-tumor M2 phenotype [15]. </plain></SENT>
<SENT sid="47" pm="."><plain>This may explain why in the early stages [16] of cancers of the lung [17], colon [18] and stomach [19], the macrophages in the normoxic milieu display an M1 phenotype and are associated with good prognosis. </plain></SENT>
</text></p><p><text><SENT sid="48" pm="."><plain>Immunohistopathological breast carcinoma studies with restricted numbers of samples (n = 53 and 120, respectively) reveal a gradual increase in the amount of infiltrating macrophages (CD68+) from normal breast tissue to benign proliferative breast disease, ductal carcinoma in situ (DCIS) and infiltrating ductal carcinoma [20, 21]. </plain></SENT>
<SENT sid="49" pm="."><plain>Two larger studies (n = 1,322 and 168, respectively) confirmed that CD68+ macrophages were associated with higher tumor grade, estrogen receptor (ER) and progesterone receptor (PR) negativity, human epithelial growth factor receptor 2 (HER-2) positivity and a basal phenotype, but led to the conclusion that CD68 expression was not an independent prognostic factor [22, 23]. </plain></SENT>
<SENT sid="50" pm="."><plain>Another breast cancer cohort study (n = 144), looking at total macrophage number (CD68+) and M2 macrophages (CD163+) found that CD163 was also associated with other prognostic markers [24]. </plain></SENT>
<SENT sid="51" pm="."><plain>It showed that CD68+ cells in the tumor stroma but not in the tumor nest were an independent prognostic factor for decreased cancer-specific survival, accounting for the localization of TAMs in the tumors more than their mere presence. </plain></SENT>
<SENT sid="52" pm="."><plain>Triple-negative/basal-like breast tumor stroma had more CD163+ and CD68+ cells and a higher proportion of CD163 relative to CD68 when compared to the stroma of luminal A tumors. </plain></SENT>
<SENT sid="53" pm="."><plain>This indicates a predominance of mature M2 macrophages and possibly immature myeloid-derived cells (MDCs, also CD163+) in triple-negative disease [24]. </plain></SENT>
</text></p><p><text><SENT sid="54" pm="."><plain>Several clinical studies have found an association between macrophage infiltration and angiogenesis in breast cancer [22, 25–28]. </plain></SENT>
<SENT sid="55" pm="."><plain>However, in relation to prognosis it is unanimous that larger studies of macrophage subpopulations are needed. </plain></SENT>
<SENT sid="56" pm="."><plain>This study intends to fill that gap. </plain></SENT>
<SENT sid="57" pm="."><plain>Focusing on the expression of M1 and M2 markers in samples from a large cohort of patients with breast cancer (n = 562), we looked for possible associations with tumor progression. </plain></SENT>
<SENT sid="58" pm="."><plain>Additionally, by studying the ex vivo differentiation of human macrophages in the presence of breast cancer conditioned media (CM), we aimed to find possible mechanisms of TAM education. </plain></SENT>
<SENT sid="59" pm="."><plain>To achieve these aims, we revisited tissue microarrays from a large cohort [29] of early human breast tumors of different subtypes, grades and aggressiveness and used different breast cancer cell lines. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="Sec2" sec-type="materials|methods"><title><text><SENT sid="60" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="Sec3"><title><text><SENT sid="61" pm="."><plain>Human samples </plain></SENT>
</text></title><p><text><SENT sid="62" pm="."><plain>TMA samples (n = 562 out of 1,199 patients from the FinXX study, NCT00114816 [29]) were studied retrospectively. </plain></SENT>
<SENT sid="63" pm="."><plain>Clinicopathological characteristics of the sub-cohort are described in Table 1. </plain></SENT>
<SENT sid="64" pm="."><plain>Formalin-fixed, paraffin-embedded tumor samples were used for TMA. </plain></SENT>
<SENT sid="65" pm="."><plain>Blocks were made using a 1.0-mm tissue cylinder through a histologically representative area of each donor tumor block. </plain></SENT>
<SENT sid="66" pm="."><plain>From each donor block, 2–4 cores were cut and 15 TMA blocks were prepared, each containing 61–84 tumor samples plus 2–3 liver samples as positive controls.Table 1Patient demographics and relevant clinical characteristicsFactorEntire seriesCD68a  P b CD163a  P b HLA-Drαa  P b ≤369&gt;369≤167.5&gt;167.5≤107&gt;107n = 562n = 277n = 274n = 270n = 267n = 280n = 275Age, years≤502139511310598112100&gt;503491821610.0931651690.6021681750.378Tumor size median≤22 mm283144132137129140138&gt;22 mm2781321420.3481321380.5451391371.000N.A.1Nodal statuspN065273728333728pN+4972502370.1692422340.4682432470.267Histological typeDuctal399181211171213204192Lobular110664369334760Other5330200.0103021&lt;0.00129230.274Histological gradeGrade 146331326162025Grade 226413811915397127132Grade 32501061400.00191152&lt;0.0011311180.518N.A.2ER statusPositive405215181214171191207Negative15762930.0035696&lt;0.00189680.065HER-2 statusPositive170858372939377Negative3921921910.9201981740.0401871980.183Biological groupER+, HER-2−314165142173123139168ER+, HER2+91503941485239ER-, HER2+79354431454138ER-, HER2−7827490.0152551&lt;0.00148300.032Ki67≤20 %27114911615896124140&gt;20 %2421041340.00592144&lt;0.0011261160.252N.A.49Results are presented as number of patients. aThe cutoff values used correspond to the median values of number of positive cells in the entire series. bChi-square test. ER estrogen receptor, HER-2 human epidermal growth factor receptor 2, N.A. not available </plain></SENT>
</text></p></sec><sec id="Sec4"><title><text><SENT sid="67" pm="."><plain>Immunohistochemical analysis </plain></SENT>
</text></title><p><text><SENT sid="68" pm="."><plain>Sections (4-μm) of the TMA blocks were stained using standard immunohistochemical techniques for the expression of CD68 (anti-SA2 antibody clone 3C6, Abcam, Cambridge, UK), CD163 (clone 10D6, Novocastra, Newcastle, UK) and HLA-DRα (Dako, Glostrup, Denmark) [30, 31] (detailed information provided in Additional file 1). </plain></SENT>
<SENT sid="69" pm="."><plain>All the stained TMA slides were scanned using an Olympus virtual microscope equipped with Dotslide using the 10× objective (Olympus BX51, Olympus, Munich, Germany), and AxioCam camera (Zeiss, Jena, Germany). </plain></SENT>
<SENT sid="70" pm="."><plain>Positively stained cells were counted using Fiji equipment version 1.48s (Wayne Rasband, NIH). </plain></SENT>
<SENT sid="71" pm="."><plain>After color deconvolution for hematoxylin and 3,3’-Diaminobenzidine (DAB), the threshold was set for macrophage visualization. </plain></SENT>
<SENT sid="72" pm="."><plain>The size limit for particle analysis was carefully chosen to include only macrophages. </plain></SENT>
<SENT sid="73" pm="."><plain>Damaged samples were excluded from the analysis. </plain></SENT>
<SENT sid="74" pm="."><plain>The data were analyzed in a double-blinded fashion. </plain></SENT>
<SENT sid="75" pm="."><plain>The investigators were blinded to the identity and clinical pathological characteristics of each sample while analyzing/scoring the macrophage content and differentiation status. </plain></SENT>
<SENT sid="76" pm="."><plain>The final numbers of positive cells per marker, per sample were passed on to hypothesis-naïve investigators who performed the statistical analysis of the cohort. </plain></SENT>
</text></p></sec><sec id="Sec5"><title><text><SENT sid="77" pm="."><plain>Cell culture </plain></SENT>
</text></title><p><text><SENT sid="78" pm="."><plain>Human breast cancer cell lines MCF-7, MDA-MB231 and T47D, obtained from American Type Culture Collection (ATCC), were grown in Roswell Park Memorial Institure (RPMI)-1640 medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10 % fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA) and 100 IU/ml penicillin and streptomycin (Gibco, Bleiswijk, Netherlands) at 37 °C in a 5 % CO2 atmosphere. </plain></SENT>
<SENT sid="79" pm="."><plain>After reaching confluence, cell culture medium was changed to medium containing only 1 % FBS and kept in culture for 72 h. </plain></SENT>
<SENT sid="80" pm="."><plain>At the end of the culture period, the CM were collected from at least three independent cell line batches from each cell type. </plain></SENT>
<SENT sid="81" pm="."><plain>The CM were centrifuged for 5 minutes at 2,800 g, aliquoted and frozen at −20 °C. </plain></SENT>
<SENT sid="82" pm="."><plain>CM were used as 50 % supplement of the macrophage differentiation culture medium together with 10 % FBS. </plain></SENT>
<SENT sid="83" pm="."><plain>The cell lines were recently authenticated by STR (Short tandem repeat) profiling by a certified cell line authentication service (DDC Medical, Fisher Scientific, London, UK). </plain></SENT>
<SENT sid="84" pm="."><plain>Mycoplasma detection was performed on a routine basis by 4’,6-Diamidino-2-phenylindole (DAPI) staining of cultured cells. </plain></SENT>
</text></p></sec><sec id="Sec6"><title><text><SENT sid="85" pm="."><plain>Peripheral blood mononuclear cell (PBMC) isolation </plain></SENT>
</text></title><p><text><SENT sid="86" pm="."><plain>PBMCs from five different donors were isolated by centrifugation over Ficoll gradient (Sigma-Aldrich, St Louis, MO, USA). </plain></SENT>
<SENT sid="87" pm="."><plain>CD14+ cells were magnetically labeled with α-CD14 microbeads and positively selected by MACS technology (Miltenyi Biotec, Cologne, Germany). </plain></SENT>
</text></p></sec><sec id="Sec7"><title><text><SENT sid="88" pm="."><plain>Macrophage differentiation </plain></SENT>
</text></title><p><text><SENT sid="89" pm="."><plain>To obtain M1, M2a and M2c macrophages, CD14+ monocytes were cultured in MEM (Lonza, Basel, Switzerland) supplemented with 10 % FBS (Gibco, Grand Island, NY, USA) (control, CTR), with IFN-γ (50 ng/ml; M1), or IL-4 (50 ng/ml; M2a), or IL-10 (50 ng/ml; M2c) for 5 days with replacement of half of the culture media at day 3 [32]. </plain></SENT>
<SENT sid="90" pm="."><plain>To assess the effect of breast cancer cell-line-secreted factors, the same differentiation protocol was carried out in the presence or absence of 50 % CM from MDA-MB231, MCF-7 or T47D cells. </plain></SENT>
<SENT sid="91" pm="."><plain>For activation status experiments (ELISA), cells were treated with LPS (10 ng/ml, Sigma-Aldrich, St Louis, MO, USA) for one additional day. </plain></SENT>
<SENT sid="92" pm="."><plain>Unless otherwise stated, all the used cytokines were from R&amp;D Systems (Minneapolis, MN, USA). </plain></SENT>
<SENT sid="93" pm="."><plain>Supernatants were collected, centrifuged for 5 minutes at 2,800 g, aliquoted and stored at −20 °C until further analysis. </plain></SENT>
<SENT sid="94" pm="."><plain>Cells were harvested with Accutase (Invitrogen, Paisley, UK), debris were removed by centrifugation (5 minutes at 400 g), and cells were used for flow cytometry analysis. </plain></SENT>
<SENT sid="95" pm="."><plain>Supernatants were used for ELISA and zymography. </plain></SENT>
</text></p></sec><sec id="Sec8"><title><text><SENT sid="96" pm="."><plain>Flow cytometry </plain></SENT>
</text></title><p><text><SENT sid="97" pm="."><plain>Ex vivo polarized macrophages were analyzed by validated flow cytometry methods [5], with the BD LSR II flow cytometer (BD Biosciences, Erembodegem-Dorp, Belgium). </plain></SENT>
<SENT sid="98" pm="."><plain>In brief, cells were washed with PBS 0.1 % BSA (Sigma-Aldrich, St Louis, MO, USA) and before staining, Fc receptors were blocked with FcR blocking reagent (BD Biosciences, Erembodegem-Dorp, Belgium): 0.2 × 106 cells were incubated with adequate antibody mixes and washed prior to analysis. </plain></SENT>
<SENT sid="99" pm="."><plain>Surface-marker expression was analyzed with flow cytometry using the following fluorochrome-labeled monoclonal antibodies: CD14-APC-Cy7 (clone61D3; eBioscience, Paris, France), CD16-PE-Cy7 (clone DJ130c; AbD Serotec, Kidlington, UK), CD64-AF488 (clone 10.1; BioLegend, San Diego, CA, USA), CD200R-PE (clone OX108; AbD Serotec, Kidlington, UK), CD163-AF647 (clone GHI/61; BD Pharmingen, Erembodegem-Dorp, Belgium), and CD86-AF488 (clone IT2.2, BD Pharmingen, Erembodegem-Dorp, Belgium). </plain></SENT>
<SENT sid="100" pm="."><plain>Equivalent amounts of isotype-matched control antibodies and unstained cells were included in all experiments as negative and autofluorescence controls. </plain></SENT>
<SENT sid="101" pm="."><plain>Data were analyzed with BD FACSDiva software, after gating on the myeloid population in the FSC/SSC plot. </plain></SENT>
<SENT sid="102" pm="."><plain>Values were expressed as the percent ratio of the median fluorescence intensity (MedFI) of the marker of interest over the MedFI of the unstained cells. </plain></SENT>
</text></p></sec><sec id="Sec9"><title><text><SENT sid="103" pm="."><plain>ELISA </plain></SENT>
</text></title><p><text><SENT sid="104" pm="."><plain>LPS-activated macrophage culture supernatants were used in ELISA for quantification of h-IL-10, h-IL-8, and h-IL-6 according to the manufacturer’s instructions (R&amp;D systems). </plain></SENT>
<SENT sid="105" pm="."><plain>h-M-CSF was quantified in breast cancer cell line CM (Duo set, R&amp;D systems, Minneapolis, MN, USA). </plain></SENT>
</text></p></sec><sec id="Sec10"><title><text><SENT sid="106" pm="."><plain>Zymography </plain></SENT>
</text></title><p><text><SENT sid="107" pm="."><plain>The potential proteolytic activity of MMPs in the supernatants of the obtained macrophages was determined by zymography as previously described [33]. </plain></SENT>
<SENT sid="108" pm="."><plain>The stained polyacrylamide-gelatin gels were observed with the Image Quant RT ECL imager. </plain></SENT>
<SENT sid="109" pm="."><plain>Densitometry of the bands corresponding to pro-MMP-9 activity (92 kDa) was performed using Fiji equipment version 1.48s (Wayne Rasband, NIH). </plain></SENT>
<SENT sid="110" pm="."><plain>Presented values are the optical densities of pro-MMP-9-digested bands normalized to the total protein content of the corresponding total cell lysate compared with the density of the equivalent background area. </plain></SENT>
</text></p></sec><sec id="Sec11"><title><text><SENT sid="111" pm="."><plain>Statistics </plain></SENT>
</text></title><p><text><SENT sid="112" pm="."><plain>TMA results were analyzed with SAS version 8.2 for Windows (SAS Institute, Cary, NC, USA) using the median values of the numbers of positive cells in the entire series as the cutoff value. </plain></SENT>
<SENT sid="113" pm="."><plain>Frequency tables were analyzed using the chi-square (χ2) test. </plain></SENT>
<SENT sid="114" pm="."><plain>Survival between groups was compared using the Kaplan-Meier life-table method and a Cox multivariate proportional hazards model. </plain></SENT>
<SENT sid="115" pm="."><plain>The log-rank test was used to confirm the robustness of the analysis. </plain></SENT>
<SENT sid="116" pm="."><plain>The subgroup analyses were performed including the macrophage markers, the subgroup variable, and their interaction in the Cox model. </plain></SENT>
<SENT sid="117" pm="."><plain>The Mann-Whitney or Kruskal-Wallis tests were applied when suitable. </plain></SENT>
<SENT sid="118" pm="."><plain>All P values are two-sided and are not adjusted for multiple testing. </plain></SENT>
<SENT sid="119" pm="."><plain>Experimental data were expressed as median ± SD, unless otherwise indicated. </plain></SENT>
<SENT sid="120" pm="."><plain>The Kruskal-Wallis test followed by Dunn’s post hoc test was employed to calculate statistically significant differences between the CTR and the various conditions, using GraphPad Prism software. </plain></SENT>
</text></p></sec><sec id="Sec12"><title><text><SENT sid="121" pm="."><plain>Study approval </plain></SENT>
</text></title><p><text><SENT sid="122" pm="."><plain>Permission to use the tissues from the FinXX study for research purposes was provided by the Finnish Ministry of Social Affairs and Health. </plain></SENT>
<SENT sid="123" pm="."><plain>The ethics committee at the Helsinki University Central Hospital (Helsinki, Finland) approved the FinXX study and the current study (permission HUS 35/13/03/02/2015). </plain></SENT>
<SENT sid="124" pm="."><plain>Ethical approval for the use of peripheral blood from healthy donors was obtained from the Nantes University Hospital Ethics Committee. </plain></SENT>
<SENT sid="125" pm="."><plain>Samples were obtained from the Établissement Français du Sang with informed consent (agreement reference NTS 2000–24, Avenant n°10). </plain></SENT>
</text></p></sec><sec id="Sec13"><title><text><SENT sid="126" pm="."><plain>Online supplemental material </plain></SENT>
</text></title><p><text><SENT sid="127" pm="."><plain>A supplemental table (Additional file 1) and supplemental figures (Additional files 2, 3, 4, 5 and 6) are available online. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="Sec14" sec-type="results"><title><text><SENT sid="128" pm="."><plain>Results </plain></SENT>
</text></title><sec id="Sec15"><title><text><SENT sid="129" pm="."><plain>Clinical significance of TAM numbers and differentiation status in breast cancer patients </plain></SENT>
</text></title><p><text><SENT sid="130" pm="."><plain>To explore the clinical relevance of TAM differentiation in breast cancer patients, we evaluated total TAM number (CD68), M1 TAM (HLA-DRα) and M2 TAM (CD163) in a large human breast cancer TMA cohort. </plain></SENT>
<SENT sid="131" pm="."><plain>There was heterogeneity among the patients in the expression levels of the different macrophage markers (Fig. 1). </plain></SENT>
<SENT sid="132" pm="."><plain>M2 macrophage number, identified as the umber of CD163+ cells, was strongly associated with fast proliferation (Ki67 positivity &gt;20 %), poor differentiation (grade 3), ER negativity and histological ductal type (Table 2). </plain></SENT>
<SENT sid="133" pm="."><plain>None of the individual markers (CD68, HLA-DRα or CD163) was on its own strongly correlated with prognosis, recurrence-free survival (RFS) or overall survival (Additional file 2). </plain></SENT>
<SENT sid="134" pm="."><plain>In the multivariate Cox model for RFS, markers such as Ki67 positivity &gt;20 %, node positivity and primary tumor size &gt;22 mm were strongly significant predictive factors (p &lt;0.001 for tumor size and &lt;0.01 for the other factors). </plain></SENT>
<SENT sid="135" pm="."><plain>In the same model CD163 was a significant factor (p = 0.011) together with other model covariates, such as ER negativity (Table 3).Fig. 1Representative images of tissue microarray (TMA) staining revealing interpatient heterogeneous macrophage marker expression levels. </plain></SENT>
<SENT sid="136" pm="."><plain>CD68 (a-d), HLA-DRIIα (e-h) and CD163 (i-l). </plain></SENT>
<SENT sid="137" pm="."><plain>Patient core overview (a, c, e, g, i, k, scale bars 200 μm) and a detailed view of selected area (b, d, f, h, j, l, scale bars 50 μm). </plain></SENT>
<SENT sid="138" pm="."><plain>Objective amplification × 10Table 2CD68+ and CD163+ cell number median values and relevant clinical characteristicsFactorN = 551CD68+ median (range) P a N = 537CD163+ median (range) P a Histological typeDuctal392418(0–3634)384208(2–1772)Lobular109249(1–3113)102106(3–802)Other50265(0–1397)&lt;0.00151127(4–1359)&lt;0.001Histological gradeGrade 146240(18–3113)42125(5–524)Grade 2257337(0–3634)250115(2–1229)Grade 3246436(0–2595)&lt;0.001243265(3–1772)&lt;0.001N.A.22ER statusPositive396340(0–3634)385131(2–1772)Negative155435(0–2595)0.006152268(6–1743)&lt;0.001HER-2 statusPositive168363(9–2673)165221(2–1772)Negative383369(0–3634)0.900372148(3–1359)0.002Biological groupER+, HER-2−307334(0–3634)296124(3–1359)ER+, HER-2+89343(12–2673)89200(2–1772)ER-, HER-2+79424(9–1306.5)76227(7–1743)ER-, HER-2−76484(0–2595)0.02376289(6–1111)&lt;0.001Ki67≤20 %265318(0–3634)254115(2–1772)&gt;20 %238431(0–2794)0.002236263(3–1743)&lt;0.001N.A.4847 aMann-Whitney or Kruskal-Wallis test. ER estrogen receptor, HER-2 human epidermal growth factor receptor 2, N.A. not availableTable 3Independent prognostic factors in Cox multivariate model for recurrence-free survival in yearsVariablesRegression coefficentStandard errorRegression coefficient/standard error χ 2  P Exp (Coef)95 % CILowerUpperER+ −0.6120.252−2.4305.9030.01510.5420.3310.888HER-2+ 0.0500.2390.2110.0450.83261.0520.6591.679Ki67 &gt;20%−0.7110.269−2.6426.9810.00820.4910.2900.832Node positivity−1.0960.394−2.7807.7300.00540.3340.1540.724Size &gt;22 mm−0.8650.237−3.65713.3720.00030.4210.2650.669Histological grade 3−0.0710.268−0.2660.0710.78990.9310.5501.575CD163 &gt;167.50.5800.2292.5316.4080.01141.7861.1402.798 ER estrogen receptor, HER-2 human epidermal growth factor receptor 2, Coef regression coefficient, χ 2 chi-squared, Exp(Coef) hazard ratio </plain></SENT>
</text></p></sec><sec id="Sec16"><title><text><SENT sid="139" pm="."><plain>Human breast cancer cells condition ex vivo differentiation and activation of human macrophages </plain></SENT>
</text></title><p><text><SENT sid="140" pm="."><plain>As a proof of concept, we showed that the isolated CD14+ cells could be differentiated to M1 (high CD64, high IL-6 secretion), M2a (high CD200R and CD86, low IL-6 and high IL-8 secretion) and M2c macrophages (high CD163, low IL-6 and high IL-10 secretion), respectively, using IFN-γ, IL-4 and IL-10, thus, demonstrating their proven [34] ex vivo plasticity (Figs. 2, 3 and 4 and Additional file 3). </plain></SENT>
<SENT sid="141" pm="."><plain>Considering M1 differentiation in the presence of IFN-γ, none of the CM affected the expression levels of M1 surface-markers (Additional file 4) nor the secretion profile (data not shown).Fig. 2Flow cytometry analysis of CD14+ cells differentiated for 5 days with or without 50 % conditioned media (CM). a-e Percentual variation of median fluorescence intensity (MedFI) of CD14, CD16, CD86, CD200R and CD163 compared to control (CTR), n = 5. f Monocyte colony stimulating factor (M-CSF) protein levels in breast cancer cell line CM (n = 3). g-i Flow cytometry analysis of CD14+ cells differentiated in the presence of IL-10 for 5 days with or without 50 % breast cancer cell line CM. </plain></SENT>
<SENT sid="142" pm="."><plain>Percent variation of MedFI of CD14, CD16 and CD163 compared to CTR (IL-10 alone). Error bars represent + SD, n = 5 *p &lt;0.05, **p &lt;0.005 (Kruskal-Wallis analysis followed by Dunn’s post hoc test). MB231, MDA-MB231 CMFig. 3Cytokine secretion profile after 24 h of lipopolysaccharide (LPS)-stimulation. a-c CD14+ cells differentiated for 5 days with or without 50 % breast cancer cell line conditioned media (CM) (d-f) in the presence of IL-4 (g-i) in the presence of IL-10. a-i All results are the mean of three experimental replicates and two biological replicates. j Representative matrix metalloproteinase (MMP)-9 zymography gel (k) relative MMP-9 activity, expressed as digested band optical density normalized to equivalent background area optical density. Error bars represent + SD, n = 3, *p &lt;0.05, **p &lt;0.005, ***p &lt;0.0005 (Kruskal-Wallis analysis followed by Dunn’s post hoc test). MB231, MDA-MB231 CM; NT, non-treatedFig. 4Flow cytometry analysis of CD14+ cells differentiated for 5 days in the presence of IL-4 with or without 50 % conditioned media (CM). a CD14loCD16lo and CD14hiCD16hi subpopulation distribution. b, d, f, h, j Overall percent variation of CD14, CD16, CD163, CD200R and CD86 median fluorescence intensity (MedFI), compared with control (CTR) (IL-4 alone) (c, e, g, i, k) CD14 CD16, CD163, CD200R and CD86 MedFI percent variation in the subpopulations CD14loCD16lo and CD14hiCD16hi. Error bars represent + SD, n = 5, *p &lt;0.05, **p &lt;0.005, ***p &lt;0.0005 (Kruskal-Wallis analysis followed by Dunn’s post hoc test). MB231, MDA-MB231 CM </plain></SENT>
</text></p><p><text><SENT sid="143" pm="."><plain>CD14+ cells differentiated in the presence of MDA-MB231 CM alone yielded an M2 macrophage population (Fig. 2a-e). </plain></SENT>
<SENT sid="144" pm="."><plain>This result was most obvious in terms of CD86, CD200R and CD163 expression levels (Fig. 2c-e). </plain></SENT>
<SENT sid="145" pm="."><plain>The differentiation only in the presence of other CM retained the control phenotype features (Fig. 2a-e and Additional file 3). </plain></SENT>
</text></p><p><text><SENT sid="146" pm="."><plain>Macrophages differentiated in the presence of MDA-MB231 CM produced higher amounts of IL-6, IL-8, IL-10 (Fig. 3a-c) and MMP-9 (Fig. 3j-k) than the CTR or other CM. </plain></SENT>
<SENT sid="147" pm="."><plain>That scenario remained true when the cells were concomitantly treated with IL-4 (Fig. 3d-f) or IL-10 (Fig. 3g-i), except for IL-6 secretion in the latter treatment (Fig. 3g). </plain></SENT>
</text></p></sec><sec id="Sec17"><title><text><SENT sid="148" pm="."><plain>MDA-MB231 cells secrete large amounts of M-CSF, skewing macrophages to an M2c-like phenotype </plain></SENT>
</text></title><p><text><SENT sid="149" pm="."><plain>The strong effects of the MDA-MB231 cells led us to inspect all the CM for dissimilarly secreted macrophage-differentiating factors. </plain></SENT>
<SENT sid="150" pm="."><plain>We saw no differences in terms of IL-10, transforming growth factor (TGF)-β or IL-4 (data not shown), but only MDA-MB231 cells secreted high amounts of M-CSF (Fig. 2f). </plain></SENT>
</text></p><p><text><SENT sid="151" pm="."><plain>CD14+ cells differentiated in the presence of IL-10 and MDA-MB231 or T47D CM (Fig. 2g-i and Additional file 5) showed a decrease in CD14 expression levels when compared to cells differentiated only with IL-10 (CTR, Fig. 2g). </plain></SENT>
<SENT sid="152" pm="."><plain>MDA-MB231 CM significantly increased CD163 expression levels (Fig. 2i). </plain></SENT>
<SENT sid="153" pm="."><plain>The macrophages treated with IL-10 and MDA-MB231 CM secreted more IL-8, IL-10 and MMP-9 than the CTR IL-10-treated macrophages (Fig. 3g-k). </plain></SENT>
</text></p></sec><sec id="Sec18"><title><text><SENT sid="154" pm="."><plain>Human breast cancer cells affect M2a macrophage differentiation, rendering macrophages to a mixed M2a/M2c phenotype </plain></SENT>
</text></title><p><text><SENT sid="155" pm="."><plain>When exposed to IL-4, two major macrophage subpopulations arose in all the conditions: CD14lo/C16lo and CD14hi/CD16hi (Fig. 4). </plain></SENT>
<SENT sid="156" pm="."><plain>In the presence of breast cancer cell line CM, the relative percentage of each of these subpopulations changed. </plain></SENT>
<SENT sid="157" pm="."><plain>Instead of a predominance of the CD14lo/C16lo population (CTR, Fig. 4a), there was a statistically significant inversion toward a predominance of the CD14hi/CD16hi population (Fig. 4a), especially in the presence of MDA-MB231 (p &lt;0.0005) or T47D CM (p &lt;0.05). </plain></SENT>
<SENT sid="158" pm="."><plain>MCF-7 CM showed the same trend reaching equilibrium between the two subpopulations not significantly statistically different from the subpopulation distribution in the CTR (IL-4 alone). </plain></SENT>
<SENT sid="159" pm="."><plain>The detailed analysis of the surface-markers from those subpopulations indicated that MDA-MB231 and T47D CM increase CD14 (Fig. 4b) and decrease CD86 overall expression (Fig. 4j). </plain></SENT>
<SENT sid="160" pm="."><plain>MDA-MB231 CM increases CD16 (Fig. 4d), CD163 (Fig. 4f) and CD200R expression (Fig. 4h). </plain></SENT>
<SENT sid="161" pm="."><plain>These fluctuations are mostly due to the CD14hi/CD16hi population (Fig. 4c, e, g, i, k) and the results were statistically significant for the global expression (Fig. 4b, d, f, h, j; p &lt;0.05). </plain></SENT>
<SENT sid="162" pm="."><plain>Although not statistically significant, MCF-7 CM induced the same trend as T47D CM (Fig. 4a-k). </plain></SENT>
</text></p><p><text><SENT sid="163" pm="."><plain>Only MDA-MB231 CM affected cytokine and MMP-9 secretion, reflecting the exceptionality of this cell line (Fig. 3d-f, j, k). </plain></SENT>
<SENT sid="164" pm="."><plain>MDA-MB231 CM in the IL-4 condition increased IL-10 secretion (Fig. 3f), and increased IL-6, IL-8 (Fig. 3d, e) and MMP-9 secretion (Fig. 3j, k). </plain></SENT>
<SENT sid="165" pm="."><plain>If compared to MDA-MB231 CM alone, IL-4 combined with MDA-MB231 CM decreased the secretion of IL-6, IL-8 and MMP-9 and increased IL-10 secretion (Fig. 3a-c and Fig. 3j, k). </plain></SENT>
<SENT sid="166" pm="."><plain>Overall, MDA-MB231 CM in the presence of IL-4 produced a macrophage subpopulation with an intermediate/mixed M2a/M2c phenotype (Additional file 6), with an abundant production of the immunosuppressive M2c-inducing cytokine IL-10. </plain></SENT>
<SENT sid="167" pm="."><plain>These macrophages retain matrix-remodeling properties by secreting MMP-9. </plain></SENT>
<SENT sid="168" pm="."><plain>The possibility that the MCF-7 or T47D CM-induced CD14hi/CD16hi macrophage subpopulations also secrete different levels of cytokines should not be discarded. </plain></SENT>
<SENT sid="169" pm="."><plain>Those more subtle differences may be masked by the higher titers produced by the MDA-MB231-CM-induced CD14hi/CD16hi subpopulations. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="Sec19" sec-type="discussion"><title><text><SENT sid="170" pm="."><plain>Discussion </plain></SENT>
</text></title><sec id="Sec20"><title><text><SENT sid="171" pm="."><plain>Clinical significance of TAM numbers and differentiation status in breast cancer patients </plain></SENT>
</text></title><p><text><SENT sid="172" pm="."><plain>In this study CD163+ cells in primary breast tumor tissue were brought up as a negative prognosis factor for RFS. </plain></SENT>
<SENT sid="173" pm="."><plain>However, we could not precisely determine which would be the additional interacting factors involved in this effect. </plain></SENT>
<SENT sid="174" pm="."><plain>It is clear that CD163 correlates with known factors to be associated with a bad prognosis, such as ER negativity, poor differentiation (grade 3) and ductal type (Tables 1 and 2). </plain></SENT>
<SENT sid="175" pm="."><plain>Previous studies have shown that higher tumor grade [22] and higher Ki67 index are associated with increased CD68+ macrophage infiltration in breast tumors [23, 35]. </plain></SENT>
<SENT sid="176" pm="."><plain>It was suggested that highly proliferative high-grade tumors elicit an active immune response that further supports angiogenesis and tumor growth. </plain></SENT>
<SENT sid="177" pm="."><plain>Further, these high-grade tumors may secrete higher levels of macrophage-recruiting/modulating cytokines such as M-CSF (ex vivo results, Fig. 2f), IL-10 and/or TGF-β [6], which is in agreement with the high number of CD163+ M2-macrophages. </plain></SENT>
<SENT sid="178" pm="."><plain>A study exploring stromal gene signatures in DCIS and invasive breast cancer found that higher grade ER-negative and PR-negative tumors are associated with macrophage responses [36]. </plain></SENT>
<SENT sid="179" pm="."><plain>Macrophage infiltration was present early in the tumor progression at the DCIS stage, and the majority of cases remained positive in matched invasive breast cancer cases, accounting for early macrophage recruitment in breast cancer progression [36]. </plain></SENT>
<SENT sid="180" pm="."><plain>Although widely accepted as a specific monocyte/macrophage marker, CD163 can also be expressed by immature MDCs, which include myeloid-derived suppressor cells (MDSCs), known to favor tumor progression [24]. </plain></SENT>
<SENT sid="181" pm="."><plain>Therefore, we cannot exclude the possibility that a percentage of the CD163+ cells detected may in fact be MDSCs, which could account for the poor prognostic role of CD163. </plain></SENT>
</text></p></sec><sec id="Sec21"><title><text><SENT sid="182" pm="."><plain>Differential ex vivo conditioning of human macrophage differentiation and activation by different breast cancer cell types </plain></SENT>
</text></title><p><text><SENT sid="183" pm="."><plain>Levano et al. [7] explored the cytokine receptor profile of different breast cancer cell types and found that basal-like cells (e.g., MDA-MB231) express preferentially granulocyte monocyte colony stimulating factor (GM-CSF), hepatocyte growth factor receptor (HGFR, also known as c-MET), CD44, epithelial growth factor receptor (EGFR), transforming growth factor receptor 2 (TGFR2) and oncostatin M receptor (OSMR). </plain></SENT>
<SENT sid="184" pm="."><plain>Luminal-type breast cancer cells (e.g., MCF-7 and T47D) express RET (a proto-oncogene which encodes for a receptor tyrosine kinase for members of the glial cell line-derived neurotrophic factor) [7] and leukemia inhibitory factor (LIF) [37]. </plain></SENT>
<SENT sid="185" pm="."><plain>This suggests that TAMs have a different influence depending on the tumor subtype, as breast cancer cells will have different receptors for TAM-derived factors [7]. </plain></SENT>
<SENT sid="186" pm="."><plain>Further, mesenchymal or epithelial-like breast cancer cells respond to or influence TAMs differently. </plain></SENT>
<SENT sid="187" pm="."><plain>It has been shown that mesenchymal-like breast cancer cells secrete GM-CSF to activate macrophages to a CCL18-expressing TAM-like phenotype and, reciprocally, these TAM-like macrophages sustain the EMT of cancer cells [38]. </plain></SENT>
<SENT sid="188" pm="."><plain>These findings are not totally unexpected when considering the role of macrophages in mammary gland development during embryogenesis, puberty, pregnancy and lactation. </plain></SENT>
<SENT sid="189" pm="."><plain>Macrophages in the mammary gland were proven essential in supporting and activating mammary stem cells necessary for normal morphogenesis [39], branching [9] and in the postpartum-related influx of M2 macrophages [10]. </plain></SENT>
<SENT sid="190" pm="."><plain>All these developmental processes occur via mechanisms similar to molecular cancer mechanisms, such as vascular endothelial growth factor A (VEGF-A)-stimulated angiogenesis. </plain></SENT>
<SENT sid="191" pm="."><plain>Additionally, TAMs secrete EGF, TNF-α, VEGF and basic fibroblast growth factor (bFGF) and have reduced antigen presenting ability. </plain></SENT>
<SENT sid="192" pm="."><plain>Also the release of IL-10 by both tumor cells and TAMs immunosuppresses cytotoxic T-lymphocytes (CTLs) [9]. </plain></SENT>
</text></p><p><text><SENT sid="193" pm="."><plain>A study of murine and human macrophage polarization profiles showed that M-CSF-differentiated human macrophages are pro-M2, meaning that LPS or IFN-γ stimulation can still induce an M1 response. </plain></SENT>
<SENT sid="194" pm="."><plain>However, if stimulated with IL-4 or IL-10 they become more M2 type than the basal macrophages [40]. </plain></SENT>
<SENT sid="195" pm="."><plain>M-CSF induces CD163 expression in macrophages which, when LPS-stimulated, secrete higher levels of IL-12p40, TNF-α and IL-6 [34]. </plain></SENT>
<SENT sid="196" pm="."><plain>Our MDA-MB231 cells produce copious amounts of M-CSF (Fig. 2f), in levels similar to clinical samples and MDA-MB231 cells, as reported previously [6]. </plain></SENT>
<SENT sid="197" pm="."><plain>Similarly, the monocyte shift toward M2/CD163+ TAMs by increased levels of M-CSF has been seen in other tumor types such as glioma [41], clear cell renal carcinoma [42], ovarian carcinoma [43] and a mouse model of osteosarcoma [44]. </plain></SENT>
<SENT sid="198" pm="."><plain>In those tumor types, the elevated M-CSF and CD163 expression correlates with higher tumor grade [41, 42]. </plain></SENT>
</text></p><p><text><SENT sid="199" pm="."><plain>CD163 is a monocyte/macrophage-restricted scavenger receptor. </plain></SENT>
<SENT sid="200" pm="."><plain>It clears hemoglobin/haptoglobin complexes, hence protecting tissues from hemoglobin-induced oxidative damage [45]. </plain></SENT>
<SENT sid="201" pm="."><plain>It was recently shown that breast cancer CD163+ TAMs correlate with Wnt5a expression, the latter factor being responsible for macrophage reprogramming to an anti-inflammatory M2 status. </plain></SENT>
<SENT sid="202" pm="."><plain>The same group has reported that Wnt5a acts as a feedback antagonist of toll-like receptor (TLR) signaling, inducing IL-10 secretion [26]. </plain></SENT>
<SENT sid="203" pm="."><plain>Our results fit this mechanism well, as MDA-MB231 CM induced CD163 expression, a feature of M2c TAMs. </plain></SENT>
<SENT sid="204" pm="."><plain>This could indicate a parallel increase in Wnt5a that inhibits TLR response and increases IL-10 secretion upon LPS stimulation (Fig. 3c, f, i). </plain></SENT>
</text></p><p><text><SENT sid="205" pm="."><plain>As previously discussed, the M2c-boosted differentiation by MDA-MB231-secreted products may have consequences in terms of microenvironment-aided tumor progression via immunosuppressive, matrix remodeling and scavenging TAM functions. </plain></SENT>
<SENT sid="206" pm="."><plain>These effects may impair an effective immune tumor rejection as our in vitro findings with murine macrophages and breast cancer cell line CM indicate [46]. </plain></SENT>
</text></p><p><text><SENT sid="207" pm="."><plain>The overall decrease of CD86 expression in M2a macrophages by breast cancer CM may contribute to immunosuppressive, tumor-promoting behavior. </plain></SENT>
<SENT sid="208" pm="."><plain>CD86, also known as B7-2, is a type I transmembrane protein of the immunoglobulin superfamily. </plain></SENT>
<SENT sid="209" pm="."><plain>It is a co-stimulatory molecule expressed by antigen-presenting cells such as dendritic cells and macrophages. </plain></SENT>
<SENT sid="210" pm="."><plain>Its binding to CD28 on naïve T-cells is essential for Th2 differentiation, cytokine secretion and induction of effector function [47]. </plain></SENT>
</text></p><p><text><SENT sid="211" pm="."><plain>In our system, M2a macrophages differentiated in the presence of IL-4 and MDA-MB231 CM had the potential for increased CD200R signaling which in vivo would indicate an immunosuppressive tumor-promoting environment. </plain></SENT>
<SENT sid="212" pm="."><plain>CD200R is a myeloid receptor expressed on macrophages, granulocytes, dendritic cells and NK (natural killer) cells [48]. </plain></SENT>
<SENT sid="213" pm="."><plain>CD200R signaling is known to increase the immune activation threshold, being physiologically relevant in restraining inflammation [48]. </plain></SENT>
<SENT sid="214" pm="."><plain>CD200 ligand interaction with its receptor CD200R on macrophages decreases TNF-α and IFN-γ secretion [49]. </plain></SENT>
<SENT sid="215" pm="."><plain>CD200 is expressed by cancer cells and other cell types like mesenchymal stem cells, thymocytes, activated T cells, B cells and dendritic cells. </plain></SENT>
<SENT sid="216" pm="."><plain>Studies in different tumor types, including breast cancer, showed that CD200-CD200R interaction delivers an immunosuppressive signal. </plain></SENT>
<SENT sid="217" pm="."><plain>This signal directly decreases inflammatory cytokine secretion by macrophages, and indirectly increases regulatory T cells (Treg) and decreases effector T-cell numbers, thereby promoting tumor progression by immune evasion [50]. </plain></SENT>
</text></p></sec><sec id="Sec22"><title><text><SENT sid="218" pm="."><plain>Limitations of the study </plain></SENT>
</text></title><p><text><SENT sid="219" pm="."><plain>In the TMA analysis the median of positive cells for each marker in all samples was used as a cutoff value and analysis of normal breast tissue - probably carrying resting macrophages as a healthy baseline control - could not be included. </plain></SENT>
<SENT sid="220" pm="."><plain>However, our study brought up differences in TAM activation status between patients relevant to the disease outcome. </plain></SENT>
<SENT sid="221" pm="."><plain>Larger studies are thus justified to ascertain the exact role of M2 macrophages in disease progression. </plain></SENT>
</text></p><p><text><SENT sid="222" pm="."><plain>In the ex vivo macrophage differentiation studies, the extrapolation of the MDA-MB231 CM effects on macrophage differentiation to the clinical situation of triple-negative breast cancer patients should be made with care. </plain></SENT>
<SENT sid="223" pm="."><plain>MDA-MB231 is an aggressive model cell line, relevant in the field as it is the parental cell line for several metastatic sub-clones widely used in experiments in vivo [51–53]. </plain></SENT>
<SENT sid="224" pm="."><plain>The MDA-MB231 cell line belongs to the mesenchymal-like subtype, while cancer cells from triple-negative breast tumors, which can be of seven different subtypes, have phenotypic diversity from epithelial to mesenchymal characters [54]. </plain></SENT>
<SENT sid="225" pm="."><plain>However, we think our study remains relevant as it shows that breast cancer cells, regardless of their hormone receptor status and epithelial/mesenchymal nature, secrete factors that educate macrophages toward M2 differentiation. </plain></SENT>
<SENT sid="226" pm="."><plain>The most aggressive one, MDA-MB231, did it most effectively. </plain></SENT>
<SENT sid="227" pm="."><plain>Further studies are needed to unveil the factors responsible for the effects seen. </plain></SENT>
<SENT sid="228" pm="."><plain>M-CSF appears to be a key factor in M2 TAM differentiation, as shown by others [6, 55], but as breast cancer cell lines (MCF-7 and T47D) that do not produce M-CSF also affected the M2 phenotype, inducing M2a differentiation, we think there are other relevant M2 skewing factors, which our work cannot address. </plain></SENT>
<SENT sid="229" pm="."><plain>The discovery of such factors is of utmost relevance, and calls for further studies. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="CONCL"><sec id="Sec23" sec-type="conclusion"><title><text><SENT sid="230" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="231" pm="."><plain>This study combines several lines of evidence for the importance of TAM polarization status in breast cancer progression. </plain></SENT>
<SENT sid="232" pm="."><plain>For the first time, it is clear that CD163+ TAMs associate with other known prognostic factors like fast proliferation, poor differentiation and ER-negativity. </plain></SENT>
<SENT sid="233" pm="."><plain>CD163+ TAMs may be associated with a decrease in RFS according to the multivariate Cox model. </plain></SENT>
<SENT sid="234" pm="."><plain>The presented ex vivo results are to our knowledge the first demonstrating the modulation of macrophage differentiation solely by breast cancer cell-secreted factors, providing evidence for the mechanisms of breast cancer macrophage education behind clinical findings. </plain></SENT>
<SENT sid="235" pm="."><plain>Particularly, the mesenchymal-type cell line MDA-MB231 polarizes macrophages toward a mixed M2a/M2c status. </plain></SENT>
<SENT sid="236" pm="."><plain>It is therefore rational to venture that the screening of TAM activation in breast cancer patients could be useful in predicting patients with a high metastatic risk. </plain></SENT>
<SENT sid="237" pm="."><plain>The knowledge of TAM activation status may allow the therapeutic targeting of TAMs, once TAMs targeting/modulating agents pass clinical trials and become widely available. </plain></SENT>
<SENT sid="238" pm="."><plain>These include bisphosphonates [56]; M-CSF and M-CSFR inhibitors and targeting antibodies [57], NCT01316822, NCT01444404; anti-macrophage migration inhibitory factor, NCT01765790 and L-MTP-PE, NCT00631631. </plain></SENT>
<SENT sid="239" pm="."><plain>There is a scarcity of therapeutic options for patients with triple-negative metastatic breast cancer, and growing resistance to the available options biased by a continuous focus on cancer cell targets, which are by nature genetically unstable and prone to mutations. </plain></SENT>
<SENT sid="240" pm="."><plain>Approaches such as ours fuel a necessary paradigm change, contributing to the notion that the immunological tumor microenvironment should be taken into account in the development of new multi-target cancer therapies. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="APPENDIX"><app-group><app id="App1"><sec id="Sec24"><title>Additional files</title><p><media position="anchor" xlink:href="13058_2015_621_MOESM1_ESM.pdf" id="MOESM1"><label>Additional file 1:</label><caption><p><text><SENT sid="241" pm="."><plain>Immunohistochemical analysis conditions. (PDF 273 kb) </plain></SENT>
</text></p></caption></media><media position="anchor" xlink:href="13058_2015_621_MOESM2_ESM.pdf" id="MOESM2"><label>Additional file 2:</label><caption><p><text><SENT sid="242" pm="."><plain>Tissue microarray (TMA) analysis of recurrence-free survival and overall survival curves related to the macrophage markers A CD68 B CD163 and C HLA-DRIIα. (PDF 22622 kb) </plain></SENT>
</text></p></caption></media><media position="anchor" xlink:href="13058_2015_621_MOESM3_ESM.pdf" id="MOESM3"><label>Additional file 3:</label><caption><p><text><SENT sid="243" pm="."><plain>Flow cytometry analysis of CD14 + cells differentiated for 5 days with or without 50 % conditioned media (CM), IFN-γ, IL-4 and IL-10 A mean fluorescence intensity (MFI) of CD14 B CD16 C CD64 D CD163 E CD86 and F CD200R, normalized to MFI of unstained cells; n = 3, *** p &lt;0.0005. (PDF 1833 kb) </plain></SENT>
</text></p></caption></media><media position="anchor" xlink:href="13058_2015_621_MOESM4_ESM.pdf" id="MOESM4"><label>Additional file 4:</label><caption><p><text><SENT sid="244" pm="."><plain>Flow cytometry analysis of CD14 + cells differentiated for 5 days in the presence of IFN-γ with or without 50 % conditioned media (CM) A mean fluorescence intensity (MFI) of CD14 B CDC16 and C CD64 normalized to MFI of unstained cells; n = 3. (PDF 2112 kb) </plain></SENT>
</text></p></caption></media><media position="anchor" xlink:href="13058_2015_621_MOESM5_ESM.pdf" id="MOESM5"><label>Additional file 5:</label><caption><p><text><SENT sid="245" pm="."><plain>Representative flow cytometry dot plot of IL-10 macrophages A human macrophages in the presence of IL-10 with or without breast cancer cell line conditioned media (CM), detected with antibodies against CD14, CD16 and CD163 B mean fluorescence intensity (MFI) of the analyzed surface-markers. (PDF 18647 kb) </plain></SENT>
</text></p></caption></media><media position="anchor" xlink:href="13058_2015_621_MOESM6_ESM.pdf" id="MOESM6"><label>Additional file 6:</label><caption><p><text><SENT sid="246" pm="."><plain>Representative flow cytometry dot plot of IL-4 macrophages A human macrophages in the presence of IL-4 with or without breast cancer cell line conditioned media (CM), detected with antibodies against CD14, CD16, CD163, CD200R and CD86 B mean fluorescence intensity (MFI) of the analyzed surface-markers. (PDF 2715 kb) </plain></SENT>
</text></p></caption></media></p></sec></app></app-group></SecTag><SecTag type="ABBR"><glossary><title>Abbreviations</title><def-list><def-item><term>ATCC</term><def><p>American Type Culture Collection</p></def></def-item><def-item><term>bFGF</term><def><p>basic fibroblast growth factor</p></def></def-item><def-item><term>BSA</term><def><p>bovine serum albumin</p></def></def-item><def-item><term>CM</term><def><p>conditioned media</p></def></def-item><def-item><term>CTC</term><def><p>circulating tumor cell</p></def></def-item><def-item><term>CTLs</term><def><p>cytotoxic T-lymphocytes</p></def></def-item><def-item><term>CTR</term><def><p>control</p></def></def-item><def-item><term>DAB</term><def><p>3,3’-Diaminobenzidine</p></def></def-item><def-item><term>DCIS</term><def><p>ductal carcinoma <italic>in situ</italic></p></def></def-item><def-item><term>DTC</term><def><p>disseminating tumor cell</p></def></def-item><def-item><term>EGF</term><def><p>epidermal growth factor</p></def></def-item><def-item><term>EGFR</term><def><p>epidermal growth factor receptor</p></def></def-item><def-item><term>ELISA</term><def><p>enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>EMT</term><def><p>epithelial to mesenchymal transition</p></def></def-item><def-item><term>ER</term><def><p>estrogen receptor</p></def></def-item><def-item><term>FBS</term><def><p>fetal bovine serum</p></def></def-item><def-item><term>GM-CSF</term><def><p>granulocyte monocyte colony stimulating factor</p></def></def-item><def-item><term>HER-2</term><def><p>human epidermal growth factor receptor 2</p></def></def-item><def-item><term>HGFR</term><def><p>hepatocyte growth factor receptor</p></def></def-item><def-item><term>IFN-γ</term><def><p>interferon γ</p></def></def-item><def-item><term>kDa</term><def><p>kiloDaltons</p></def></def-item><def-item><term>LIF</term><def><p>leukemia inhibitory factor</p></def></def-item><def-item><term>LPS</term><def><p>lipopolysaccharide</p></def></def-item><def-item><term>M-CSF</term><def><p>monocyte colony stimulating factor</p></def></def-item><def-item><term>M-CSFR</term><def><p>monocyte colony stimulating factor receptor</p></def></def-item><def-item><term>MDCs</term><def><p>myeloid-derived cells</p></def></def-item><def-item><term>MDSCs</term><def><p>myeloid-derived suppressor cells</p></def></def-item><def-item><term>MedFI</term><def><p>median fluorescence intensity</p></def></def-item><def-item><term>MMP-9</term><def><p>matrix metalloproteinase 9</p></def></def-item><def-item><term>MMPs</term><def><p>matrix metalloproteinases</p></def></def-item><def-item><term>NK</term><def><p>natural killer</p></def></def-item><def-item><term>OSMR</term><def><p>oncostatin M receptor</p></def></def-item><def-item><term>PBMCs</term><def><p>peripheral blood mononuclear cells</p></def></def-item><def-item><term>PBS</term><def><p>phosphate-buffered saline</p></def></def-item><def-item><term>PR</term><def><p>progesterone receptor</p></def></def-item><def-item><term>RET</term><def><p>proto-oncogene, which encodes for a receptor tyrosine kinase for members of the glial cell line-derived neurotrophic factor</p></def></def-item><def-item><term>RFS</term><def><p>recurrence-free survival</p></def></def-item><def-item><term>RNS</term><def><p>reactive nitrogen species</p></def></def-item><def-item><term>ROS</term><def><p>reactive oxygen species</p></def></def-item><def-item><term>TAMs</term><def><p>tumor-associated macrophages</p></def></def-item><def-item><term>TGFR2</term><def><p>transforming growth factor receptor 2</p></def></def-item><def-item><term>TGF-β</term><def><p>transforming growth factor β</p></def></def-item><def-item><term>TLR</term><def><p>toll-like receptor</p></def></def-item><def-item><term>TMA</term><def><p>tissue microarray</p></def></def-item><def-item><term>TNF-α</term><def><p>tumor necrosis factor α</p></def></def-item><def-item><term>Treg</term><def><p>regulatory T-cells</p></def></def-item><def-item><term>VCAM1</term><def><p>vascular cell adhesion molecule 1</p></def></def-item><def-item><term>VEGF-A</term><def><p>vascular endothelial growth factor A</p></def></def-item></def-list></glossary></SecTag><fn-group><fn><p><text><SENT sid="247" pm="."><plain>Competing interests </plain></SENT>
</text></p><p><text><SENT sid="248" pm="."><plain>The authors declare that they have no competing interests. </plain></SENT>
</text></p></fn><SecTag type="ACK_FUND"><fn><p><text4fund><text><SENT sid="249" pm="."><plain>Authors’ contributions </plain></SENT>
</text></text4fund></p><p><text4fund><text><SENT sid="250" pm="."><plain>SS conceived and designed the study, developed the methodology, acquired, analyzed and interpreted the data and wrote and revised the manuscript. </plain></SENT>
<SENT sid="251" pm="."><plain>RB acquired the flow cytometry data. </plain></SENT>
<SENT sid="252" pm="."><plain>ML, PK and JS provided technical support in the TMA analysis. </plain></SENT>
<SENT sid="253" pm="."><plain>SL and OT participated in the TMA study and performed its statistical analysis. </plain></SENT>
<SENT sid="254" pm="."><plain>HJ participated in the TMA study, acquiring, analyzing, and interpreting the data. </plain></SENT>
<SENT sid="255" pm="."><plain>DH participated in the study conception and design particularly in supervising the ex vivo macrophage differentiation studies. </plain></SENT>
<SENT sid="256" pm="."><plain>JuM supervised and coordinated the study. </plain></SENT>
<SENT sid="257" pm="."><plain>JM conceived, designed, supervised and participated in the manuscript writing and revision. </plain></SENT>
<SENT sid="258" pm="."><plain>All authors read, revised critically for important intellectual content and approved the final manuscript. </plain></SENT>
</text></text4fund></p></fn></SecTag></fn-group><SecTag type="ACK_FUND"><ack><title>Acknowledgements</title><p><text4fund><text><SENT sid="259" pm="."><plain>The current research was funded by the Seventh Framework Programme [FP7/2007-2013] under grant agreement no.264817 – BONE-NET and by the Academy of Finland, decision numbers 132389 and 250917. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list id="Bib1"><title>References</title><ref id="CR1"><text><SENT sid="260" pm="."><plain>1.ChambersAFGroomACMacDonaldICDissemination and growth of cancer cells in metastatic sitesNat Rev Cancer.200225637210.1038/nrc865<?supplied-pmid 12154349?>12154349 </plain></SENT>
</text></ref><ref id="CR2"><text><SENT sid="261" pm="."><plain>2.BingleLBrownNJLewisCEThe role of tumour-associated macrophages in tumour progression: implications for new anticancer therapiesJ Pathol.20021962546510.1002/path.1027<?supplied-pmid 11857487?>11857487 </plain></SENT>
</text></ref><ref id="CR3"><text><SENT sid="262" pm="."><plain>3.PollardJWMacrophages define the invasive microenvironment in breast cancerJ Leukocyte Biol.2008846233010.1189/jlb.1107762<?supplied-pmid 18467655?>18467655 </plain></SENT>
</text></ref><ref id="CR4"><text><SENT sid="263" pm="."><plain>4.MosserDMEdwardsJPExploring the full spectrum of macrophage activationNat Rev Immunol.200889586910.1038/nri2448<?supplied-pmid 19029990?>19029990 </plain></SENT>
</text></ref><ref id="CR5"><text><SENT sid="264" pm="."><plain>5.AmbarusCAKrauszSvan EijkMHamannJRadstakeTRReedquistKASystematic validation of specific phenotypic markers for in vitro polarized human macrophagesJ Immunol Methods.201237519620610.1016/j.jim.2011.10.013<?supplied-pmid 22075274?>22075274 </plain></SENT>
</text></ref><ref id="CR6"><text><SENT sid="265" pm="."><plain>6.GruganKDMcCabeFLKinderMGreenplateARHarmanBCEkertJETumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor functionJ Immunol.201218954576610.4049/jimmunol.1201889<?supplied-pmid 23105143?>23105143 </plain></SENT>
</text></ref><ref id="CR7"><text><SENT sid="266" pm="."><plain>7.LevanoKSJungEHKennyPABreast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokinesBiochem Biophys Res Commun.20114111071010.1016/j.bbrc.2011.06.102<?supplied-pmid 21712030?>21712030 </plain></SENT>
</text></ref><ref id="CR8"><text><SENT sid="267" pm="."><plain>8.MantovaniASozzaniSLocatiMAllavenaPSicaAMacrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytesTrends Immunol.2002235495510.1016/S1471-4906(02)02302-5<?supplied-pmid 12401408?>12401408 </plain></SENT>
</text></ref><ref id="CR9"><text><SENT sid="268" pm="."><plain>9.GyorkiDAsselin-LabatMvan RooijenNLindemanGVisvaderJResident macrophages influence stem cell activity in the mammary glandBreast Cancer Res.200911R6210.1186/bcr2353<?supplied-pmid 19706193?>19706193 </plain></SENT>
</text></ref><ref id="CR10"><text><SENT sid="269" pm="."><plain>10.O'BrienJMartinsonHDurand-RougelyCSchedinPMacrophages are crucial for epithelial cell death and adipocyte repopulation during mammary gland involutionDevelopment.20121392697510.1242/dev.071696<?supplied-pmid 22129827?>22129827 </plain></SENT>
</text></ref><ref id="CR11"><text><SENT sid="270" pm="."><plain>11.QianBLiJZhangHKitamuraTZhangJCampionLRCCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasisNature.2011475222510.1038/nature10138<?supplied-pmid 21654748?>21654748 </plain></SENT>
</text></ref><ref id="CR12"><text><SENT sid="271" pm="."><plain>12.WyckoffJWangWLinEYWangYPixleyFStanleyERA paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumorsCancer Res.2004647022910.1158/0008-5472.CAN-04-1449<?supplied-pmid 15466195?>15466195 </plain></SENT>
</text></ref><ref id="CR13"><text><SENT sid="272" pm="."><plain>13.ChenQZhangXHMassaguéJMacrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungsCancer Cell.2011205384910.1016/j.ccr.2011.08.025<?supplied-pmid 22014578?>22014578 </plain></SENT>
</text></ref><ref id="CR14"><text><SENT sid="273" pm="."><plain>14.CasazzaALaouiDWenesMRizzolioSBassaniNMambrettiMImpeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunityCancer Cell.20132469570910.1016/j.ccr.2013.11.007<?supplied-pmid 24332039?>24332039 </plain></SENT>
</text></ref><ref id="CR15"><text><SENT sid="274" pm="."><plain>15.MovahediKLaouiDGysemansCBaetenMStangéGVan BosscheJDDifferent tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytesCancer Res.20107057283910.1158/0008-5472.CAN-09-4672<?supplied-pmid 20570887?>20570887 </plain></SENT>
</text></ref><ref id="CR16"><text><SENT sid="275" pm="."><plain>16.BiswasSKSicaALewisCEPlasticity of macrophage function during tumor progression: Regulation by distinct molecular mechanismsJ Immunol.20081802011710.4049/jimmunol.180.4.2011<?supplied-pmid 18250403?>18250403 </plain></SENT>
</text></ref><ref id="CR17"><text><SENT sid="276" pm="."><plain>17.OhriCMShikotraAGreenRHWallerDABraddingPMacrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survivalEur Respir J.2009331182610.1183/09031936.00065708<?supplied-pmid 19118225?>19118225 </plain></SENT>
</text></ref><ref id="CR18"><text><SENT sid="277" pm="."><plain>18.ForssellJÖbergÅHenrikssonMLStenlingRJungAPalmqvistRHigh macrophage infiltration along the tumor front correlates with improved survival in colon cancerClin Cancer Res.2007131472910.1158/1078-0432.CCR-06-2073<?supplied-pmid 17332291?>17332291 </plain></SENT>
</text></ref><ref id="CR19"><text><SENT sid="278" pm="."><plain>19.OhnoSInagawaHDharDKFujiiTUedaSTachibanaMThe degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patientsAnticancer Res.200323501522<?supplied-pmid 14981961?>14981961 </plain></SENT>
</text></ref><ref id="CR20"><text><SENT sid="279" pm="."><plain>20.HusseinMRHassanHIAnalysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observationsJ Clin Pathol.200659972710.1136/jcp.2005.031252<?supplied-pmid 16935972?>16935972 </plain></SENT>
</text></ref><ref id="CR21"><text><SENT sid="280" pm="."><plain>21.VolodkoNReinerARudasMJakeszRTumour-associated macrophages in breast cancer and their prognostic correlationsBreast.199879910510.1016/S0960-9776(98)90065-0 </plain></SENT>
</text></ref><ref id="CR22"><text><SENT sid="281" pm="."><plain>22.MahmoudSMALeeAHSPaishECMacmillanRDEllisIOGreenARTumour-infiltrating macrophages and clinical outcome in breast cancerJ Clin Pathol.2012651596310.1136/jclinpath-2011-200355<?supplied-pmid 22049225?>22049225 </plain></SENT>
</text></ref><ref id="CR23"><text><SENT sid="282" pm="."><plain>23.Al MurriAMHilmyMBellJWilsonCMcNicolAMLanniganAThe relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancerBr J Cancer.2008991013910.1038/sj.bjc.660466718797461 </plain></SENT>
</text></ref><ref id="CR24"><text><SENT sid="283" pm="."><plain>24.MedrekCPontenFJirstromKLeanderssonKThe presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patientsBMC Cancer.201212306-2407-12-30610.1186/1471-2407-12-30622824040 </plain></SENT>
</text></ref><ref id="CR25"><text><SENT sid="284" pm="."><plain>25.LeekRDLewisCEWhitehouseRGreenallMClarkeJHarrisALAssociation of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinomaCancer Res.19965646259<?supplied-pmid 8840975?>8840975 </plain></SENT>
</text></ref><ref id="CR26"><text><SENT sid="285" pm="."><plain>26.BergenfelzCMedrekCEkströmEJirströmKJanolsHWulltMWnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patientsJ Immunol.201218854485810.4049/jimmunol.1103378<?supplied-pmid 22547701?>22547701 </plain></SENT>
</text></ref><ref id="CR27"><text><SENT sid="286" pm="."><plain>27.KrólMMuchaJMajchrzakKHomaABulkowskaMMajewskaAMacrophages mediate a switch between canonical and non-canonical wnt pathways in canine mammary tumorsPLoS ONE.20149e8399510.1371/journal.pone.0083995<?supplied-pmid 24404146?>24404146 </plain></SENT>
</text></ref><ref id="CR28"><text><SENT sid="287" pm="."><plain>28.OjalvoLSWhittakerCACondeelisJSPollardJWGene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumorsJ Immunol.20101847021210.4049/jimmunol.0902360<?supplied-pmid 20018620?>20018620 </plain></SENT>
</text></ref><ref id="CR29"><text><SENT sid="288" pm="."><plain>29.JoensuuHKellokumpu-LehtinenPHuovinenRJukkola-VuorinenATannerMAsolaRAdjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trialLancet Oncol.20091011455110.1016/S1470-2045(09)70307-9<?supplied-pmid 19906561?>19906561 </plain></SENT>
</text></ref><ref id="CR30"><text><SENT sid="289" pm="."><plain>30.BuddinghEPKuijjerMLDuimRAJBürgerHAgelopoulosKMyklebostOTumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: A rationale for treatment with macrophage activating agentsClin Cancer Res.2011172110910.1158/1078-0432.CCR-10-2047<?supplied-pmid 21372215?>21372215 </plain></SENT>
</text></ref><ref id="CR31"><text><SENT sid="290" pm="."><plain>31.AmbarusCASantegoetsKCvan BonLWeninkMHTakPPRadstakeTRSoluble immune complexes shift the TLR-induced cytokine production of distinct polarized human macrophage subsets towards IL-10PLoS One.20127e3599410.1371/journal.pone.0035994<?supplied-pmid 22563430?>22563430 </plain></SENT>
</text></ref><ref id="CR32"><text><SENT sid="291" pm="."><plain>32.GuihardPDangerYBrounaisBDavidEBrionRDelecrinJInduction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signalingStem Cells.2012307627210.1002/stem.1040<?supplied-pmid 22267310?>22267310 </plain></SENT>
</text></ref><ref id="CR33"><text><SENT sid="292" pm="."><plain>33.DamiensCFortunYCharrierCHeymannDPadrinesMModulation by soluble factors of gelatinase activities released by osteoblastic cellsCytokine.20001217273110.1006/cyto.2000.0765<?supplied-pmid 11052827?>11052827 </plain></SENT>
</text></ref><ref id="CR34"><text><SENT sid="293" pm="."><plain>34.VogelDYSGlimJEStavenuiterAWDBreurMHeijnenPAmorSHuman macrophage polarization in vitro: Maturation and activation methods comparedImmunobiology.201421969570310.1016/j.imbio.2014.05.002<?supplied-pmid 24916404?>24916404 </plain></SENT>
</text></ref><ref id="CR35"><text><SENT sid="294" pm="."><plain>35.LinEYPollardJWTumor-associated macrophages press the angiogenic switch in breast cancerCancer Res.2007675064610.1158/0008-5472.CAN-07-0912<?supplied-pmid 17545580?>17545580 </plain></SENT>
</text></ref><ref id="CR36"><text><SENT sid="295" pm="."><plain>36.SharmaMBeckAHWebsterJAEspinosaIMontgomeryKVarmaSAnalysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situBreast Cancer Res Treat.201012339740410.1007/s10549-009-0654-0<?supplied-pmid 19949854?>19949854 </plain></SENT>
</text></ref><ref id="CR37"><text><SENT sid="296" pm="."><plain>37.EstrovZSamalBLapushinRKellokumpu-LehtinenPSahinAAKurzrockRLeukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferationJ Interferon Cytokine Res.1995159051310.1089/jir.1995.15.905<?supplied-pmid 8564713?>8564713 </plain></SENT>
</text></ref><ref id="CR38"><text><SENT sid="297" pm="."><plain>38.SuSLiuQChenJChenJChenFHeCA Positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasisCancer Cell.2014256052010.1016/j.ccr.2014.03.021<?supplied-pmid 24823638?>24823638 </plain></SENT>
</text></ref><ref id="CR39"><text><SENT sid="298" pm="."><plain>39.Kellokumpu-LehtinenPJohanssonRMPelliniemiLJUltrastructure of human fetal mammary glandAnat Rec.1987218667210.1002/ar.1092180111<?supplied-pmid 3605662?>3605662 </plain></SENT>
</text></ref><ref id="CR40"><text><SENT sid="299" pm="."><plain>40.JaguinMHoulbertNFardelOLecureurVPolarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF originCell Immunol.2013281516110.1016/j.cellimm.2013.01.010<?supplied-pmid 23454681?>23454681 </plain></SENT>
</text></ref><ref id="CR41"><text><SENT sid="300" pm="."><plain>41.KomoharaYOhnishiKKuratsuJTakeyaMPossible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomasJ Pathol.2008216152410.1002/path.2370<?supplied-pmid 18553315?>18553315 </plain></SENT>
</text></ref><ref id="CR42"><text><SENT sid="301" pm="."><plain>42.KomoharaYHasitaHOhnishiKFujiwaraYSuzuSEtoMMacrophage infiltration and its prognostic relevance in clear cell renal cell carcinomaCancer Sci.201110214243110.1111/j.1349-7006.2011.01945.x<?supplied-pmid 21453387?>21453387 </plain></SENT>
</text></ref><ref id="CR43"><text><SENT sid="302" pm="."><plain>43.DulucDDelnesteYTanFMolesMPGrimaudLLenoirJTumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cellsBlood.200711043193010.1182/blood-2007-02-072587<?supplied-pmid 17848619?>17848619 </plain></SENT>
</text></ref><ref id="CR44"><text><SENT sid="303" pm="."><plain>44.SégalinyAIMohamadiADizierBLokajczykABrionRLanelRInterleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitmentInt J of Cancer.2015137738510.1002/ijc.2937625471534 </plain></SENT>
</text></ref><ref id="CR45"><text><SENT sid="304" pm="."><plain>45.SchaerCAVallelianFImhofASchoedonGSchaerDJCD163-expressing monocytes constitute an endotoxin-sensitive Hb clearance compartment within the vascular systemJ Leukoc Biol.2007821061010.1189/jlb.0706453<?supplied-pmid 17460152?>17460152 </plain></SENT>
</text></ref><ref id="CR46"><text><SENT sid="305" pm="."><plain>46.SousaSAuriolaSMonkkonenJMaattaJLiposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cellsBMC Cancer.201515410.1186/s12885-015-1005-7<?supplied-pmid 25588705?>25588705 </plain></SENT>
</text></ref><ref id="CR47"><text><SENT sid="306" pm="."><plain>47.SantinADHermonatPLRavaggiAChiriva-InternatiMCannonMJHiserodtJCExpression of surface antigens during the differentiation of human dendritic cells vs macrophages from blood monocytes in vitroImmunobiology.199920018720410.1016/S0171-2985(99)80069-2<?supplied-pmid 10416127?>10416127 </plain></SENT>
</text></ref><ref id="CR48"><text><SENT sid="307" pm="."><plain>48.RygielTPMeyaardLCD200R signaling in tumor tolerance and inflammation: A tricky balanceCurr Opin Immunol.201224233810.1016/j.coi.2012.01.002<?supplied-pmid 22264927?>22264927 </plain></SENT>
</text></ref><ref id="CR49"><text><SENT sid="308" pm="."><plain>49.PietiläMLehtonenSTuovinenELähteenmäkiKLaitinenSLeskeläHVCD200 positive human mesenchymal stem cells suppress TNF-alpha secretion from CD200 receptor positive macrophage-like cellsPLoS ONE.20127e3167110.1371/journal.pone.0031671<?supplied-pmid 22363701?>22363701 </plain></SENT>
</text></ref><ref id="CR50"><text><SENT sid="309" pm="."><plain>50.GorczynskiRMChenZKhatriIPodnosAYuKCure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signalingBreast Cancer Res Treat.20131422718210.1007/s10549-013-2735-3<?supplied-pmid 24166280?>24166280 </plain></SENT>
</text></ref><ref id="CR51"><text><SENT sid="310" pm="."><plain>51.PeyruchaudOWindingBPécheurISerreCDelmasPClézardinPEarly detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the Use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesionsJ Bone Miner Res.20011620273410.1359/jbmr.2001.16.11.2027<?supplied-pmid 11697798?>11697798 </plain></SENT>
</text></ref><ref id="CR52"><text><SENT sid="311" pm="."><plain>52.KangYSiegelPMShuWDrobnjakMKakonenSMCordón-CardoCA multigenic program mediating breast cancer metastasis to boneCancer Cell.200335374910.1016/S1535-6108(03)00132-6<?supplied-pmid 12842083?>12842083 </plain></SENT>
</text></ref><ref id="CR53"><text><SENT sid="312" pm="."><plain>53.MinnAJGuptaGPSiegelPMBosPDShuWGiriDDGenes that mediate breast cancer metastasis to lungNature.20054365182410.1038/nature03799<?supplied-pmid 16049480?>16049480 </plain></SENT>
</text></ref><ref id="CR54"><text><SENT sid="313" pm="."><plain>54.LehmannBDBauerJAChenXSandersMEChakravarthyABShyrYIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest.201112127506010.1172/JCI45014<?supplied-pmid 21633166?>21633166 </plain></SENT>
</text></ref><ref id="CR55"><text><SENT sid="314" pm="."><plain>55.SolinasGSchiareaSLiguoriMFabbriMPesceSZammataroLTumor-conditioned macrophages secrete migration-stimulating factor: A new marker for M2-polarization, influencing tumor cell motilityJ Immunol.20101856425210.4049/jimmunol.1000413<?supplied-pmid 20530259?>20530259 </plain></SENT>
</text></ref><ref id="CR56"><text><SENT sid="315" pm="."><plain>56.GnantMClézardinPDirect and indirect anticancer activity of bisphosphonates: A brief review of published literatureCancer Treat Rev.2012384071510.1016/j.ctrv.2011.09.003<?supplied-pmid 21983264?>21983264 </plain></SENT>
</text></ref><ref id="CR57"><text><SENT sid="316" pm="."><plain>57.SégalinyAITellez-GabrielMHeymannMHeymannDReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersJ Bone Oncol.2015411210.1016/j.jbo.2015.01.001 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
